Prima BioMed Ltd (NASDAQ:IMMP) Stock Has Average Target Price of $110.00 According to Analysts

Prima BioMed Ltd (NASDAQ:IMMP) has received an average rating of “Hold” from the five research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $110.00.

A number of equities analysts have recently issued reports on the company. Jefferies Financial Group upgraded Prima BioMed from a “hold” rating to a “strong-buy” rating in a report on Monday, September 14th. Weiss Ratings reissued a “sell (e+)” rating on shares of Prima BioMed in a report on Tuesday, October 6th.

Prima BioMed Price Performance

Shares of Prima BioMed stock opened at $3.20 on Monday. Prima BioMed has a 1 year low of $3.06 and a 1 year high of $70.60. The stock has a fifty day moving average price of $6.17 and a 200-day moving average price of $7.67.

Prima BioMed (NASDAQ:IMMP) last released its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($1.80) EPS for the quarter. The business had revenue of $3.68 million for the quarter.

Prima BioMed Company Profile

Prima BioMed Limited was an Australian biotechnology company focused on developing immunotherapies for cancer and other serious diseases. The company’s research centered on treatments designed to activate or enhance the immune system’s ability to recognize and attack abnormal cells.

Its principal programs included LAG-3–targeted therapies, including IMP321, later known as eftilagimod alpha or efti, an investigational soluble LAG-3 protein intended to stimulate immune responses when used alone or in combination with other cancer treatments.